Sign inJoin waitlistJoin the waitlist

Han Zhu

Director, Stanford Translational Cardio-Oncology · Stanford Health Care

Credentials: · · · ·

History

Stanford Health Care
Present
Stanford Health Care
Present
University of Colorado School of Medicine
Present

Cardiovascular Disease
Stanford Health Care
2017–2020
Internal Medicine
Stanford University
2014–2017
Case Western Reserve Univ Sch of Med
2010–2014

Research

miR-222 is necessary for exercise-induced cardiac growth and protects against pathological cardiac remodeling
Cell Metabolism · 2015 · 335 citations
Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor-Induced Myocarditis
Circulation · 2022 · First of 17 authors · 162 citations
Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response
Review · Current Cardiology Reports · 2020 · First of 10 authors · 125 citations

Ronald Witteles
17 papers
Sean Wu
16 papers
Sarah Waliany
15 papers · 15 as a resident
Joel Neal
12 papers
Heather Wakelee
7 papers
Patricia Nguyen
7 papers
Javid Moslehi
6 papers
Aarti Asnani
5 papers
Paul Cheng
5 papers
Alice Fan
4 papers
Evaline Cheng
4 papers · 4 as a fellow
Gerald Berry
4 papers

Grants

A Targeted Approach to Treat Immunotherapy-Induced Myocarditis with CXCR3 Blockade
National Heart, Lung, and Blood Institute · R01
Contact PI · $1.5M · Stanford University
2025–2029
Investigating CXCR3 Blockade as Precision Therapy for Cardiac Sarcoidosis Using Single-Cell Multi-Omics and TCR Phenotyping
National Heart, Lung, and Blood Institute · R01
Contact PI · $2.2M · Stanford University
2024–2029
Identification of Causal T-Cell Mechanisms in Immune Checkpoint Inhibitor Induced Myocarditis
National Heart, Lung, and Blood Institute · K08
Contact PI · $880K · Stanford University
2022–2026
CXCL9/10 Macrophage Induced CXCR3+ T-Cell Recruitment to the Heart Contributes to Immunotherapy Myocarditis
National Heart, Lung, and Blood Institute · R03
Contact PI · $235.7K · Stanford University
2024–2026